세계의 크립토콕쿠스증 치료제 시장 - 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

Cryptococcosis Therapeutics Market size is expected to record a 4.7% CAGR between 2024 and 2032, driven by the rising HIV/AIDS patient population.

Researchers are actively developing and refining treatments for cryptococcosis, a condition that predominantly affects those with compromised immune systems. These intensified efforts aim to enhance existing antifungal therapies and introduce new drugs, effectively managing cryptococcosis, especially in the growing HIV/AIDS demographic. This focus not only addresses the medical needs but also aims to uplift the health outcomes of those affected. According to WHO, as of the end of 2023, approximately 39.9 million individuals were living with HIV. This expanding demographic underscores the pressing demand for advanced therapeutics to counteract the heightened risk of fungal infections in immunocompromised patients.

The cryptococcosis therapeutics industry is segmented based on treatment, route of administration, drug type, distribution channel, and region.

The market share from the generics drug type segment is expected to grow substantially through 2032, due to expanding adoption for a diverse range of effective therapeutics. Generics are becoming pivotal in treatment protocols, given their proven efficacy and cost-effectiveness over brand-name counterparts. With a rising need for affordable treatments, the availability of generics is rising to cater to the demand for accessible cryptococcosis care. Furthermore, ongoing advancements are amplifying the effectiveness of these drugs and diversifying their applications.

In terms of distribution channel, the cryptococcosis therapeutics market from the online pharmacies segment is slated to generate notable revenue during 2024-2032. This surge is attributed to the growing emphasis on simplifying access to antifungal medications for patients. Online platforms are not just facilitating prescription acquisitions but are also streamlining the entire medication procurement process, ensuring individuals can conveniently access their required treatments. To bolster this, online pharmacies are refining their distribution networks, aiming for quicker delivery times and a broader therapeutic range.

Europe cryptococcosis therapeutics industry size is likely to record a notable growth rate through 2032 driven by global health initiatives. Recent endeavors have focused on enhancing access to key antifungal treatments, such as fluconazole and itraconazole, pivotal for cryptococcosis management. These initiatives not only boost treatment accessibility but also emphasize affordability. Furthermore, collaborations between health organizations and local agencies will promise to sustain these advancements, ensuring they adapt to the evolving patient needs across the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of cryptococcal infections
    • 3.2.1.2 Advancements in diagnostic technologies
    • 3.2.1.3 Development of novel antifungal drugs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Antifungal resistance
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Flucytosine
• 5.3 Amphotericin B
• 5.4 Fluconazole
• 5.5 Other treatments

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Intravenous
• 6.4 Inhalation

Chapter 7 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Branded
• 7.3 Generic

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Astellas Pharma Inc.
• 10.2 Abbott Laboratories
• 10.3 Bausch Health
• 10.4 Bristol-Myers Squibb Company
• 10.5 Glenmark Pharmaceuticals
• 10.6 Janssen Biotech Inc. (Johnson and Johnson)
• 10.7 Merck and Co., Inc.
• 10.8 Novartis AG
• 10.9 NuCare Pharmaceuticals, Inc.
• 10.10 Pfizer Inc.
• 10.11 Sigmapharm Laboratories LLC
• 10.12 Sun Pharmaceutical Industries Ltd.
• 10.13 Valeant Pharmaceuticals Inc.
• 10.14 Viamet Pharmaceutical Inc.